HER2/neu expression status of post BCG recurrent non-muscle-invasive bladder urothelial carcinomas in relation to their primary ones

Mohamed Yousef Ali; Ahmed Yousef Aboelsaad; Ahmed M. Abdel Gawad; Tamer A. Abouelgreed; Ahmed A. El Gammal; Osama M. Ghoneimy; Eman M. El-Dydamony; Ahmed A Alrefaey; Eslam Mohamed; Sherif Azzam; Ayman Abdulmohaymen; Yasien Mohammed; Mohammed S. Abdelwahed; Ahmed Fawzi A. Elsayed; Basem A. Fathi; Nosaiba M. Abd Alrahim; Abeer S. Farag; Alaa R. Mahmoud; Hasan Ismail Mohamed; Seth Horsu; Abdulkarim Hasan

doi:10.4081/aiua.2023.11313

Authors

Mohamed Yousef Ali Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Ahmed Yousef Aboelsaad Urology Department, Damietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Ahmed M. Abdel Gawad Urology Department, Damietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt. https://orcid.org/0000-0001-7051-6019
Tamer A. Abouelgreed Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Ahmed A. El Gammal Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt. https://orcid.org/0000-0002-6784-1790
Osama M. Ghoneimy Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt. https://orcid.org/0000-0002-8207-3451
Eman M. El-Dydamony Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Ahmed A Alrefaey Urology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Eslam Mohamed Clinical Oncology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Sherif Azzam Clinical Oncology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Ayman Abdulmohaymen Surgical Oncology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Yasien Mohammed Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. https://orcid.org/0000-0002-1290-5910
Mohammed S. Abdelwahed Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo; Pathology Department, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia, Egypt.
Ahmed Fawzi A. Elsayed Urology Department, Damietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Basem A. Fathi Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt. https://orcid.org/0000-0001-8245-5428
Nosaiba M. Abd Alrahim Clinical pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Abeer S. Farag Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Alaa R. Mahmoud Urology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt.
Hasan Ismail Mohamed Urology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Seth Horsu Histopathology Department, St. Vincent’s University Hospital, Dublin, Ireland.
Abdulkarim Hasan
doctorabdulkarim7@gmail.com
Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. https://orcid.org/0000-0003-0391-306X

Background: Transurethral resection (TUR) followed by adjuvant therapy is still the treatment of choice of Non-Muscle-Invasive Bladder Urothelial Carcinoma (NMIBUC). However, recurrence is one of the most troublesome features of these lesions. Early second resection and adjuvant BCG therapy has been shown to improve the outcome. Objective: To evaluate the prognostic value of C-erbB-2 (HER2/neu) expression status in Non-Muscle-Invasive Bladder Urothelial Carcinoma cases, before and after intravesical Bacillus Calmette Guerin (BCG immunotherapy). Materials and methods: HER2/neu expression was studied in 120 (Ta-T1) Non-Muscle-Invasive Urothelial Carcinoma cases. The expression was evaluated and compared to the expression after Bacillus Calmette Guerin (BCG) immunotherapy. Results: HER2/neu expression in low and high grade of the Non- Muscle-Invasive Urothelial Carcinoma was (38%) and (83%) respectively. The difference of the expression rates by tumor grade was statistically significant. In recurring lesions post BCG therapy, C-erbB-2 expression was markedly decreased (31.6%) when compared to its expression before therapy (65%). Conclusions: The HER2/neu expression increased as the tumor grade rose. The reduction in expression following BCG treatment in Non-Invasive transitional cell carcinoma cases could reflect a reduction of the potential malignancy of the tumor.

Compérat E, Larré S, Roupret M, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 2015; 466:589.

Babjuk M, Burger M, Compérat EM, et al. European Association of Urology guidelines on non muscle-invasive urothelial carcinoma of the bladder (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 2019; 76:639-657.

de Goeij L, Westhoff E, Witjes JA, et al. The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle- invasive bladder cancer prognosis and health-related quality of life. BMJ Open. 2019; 9:e030396.

Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56:247-256.

Zhao J, Xu W, Zhang Z, et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2015; 47:87-94.

Babjuk M, Burger M, Compérat E. EAU guidelines on non-muscle-invasive bladder cancer. Arnhem, The Netherlands: European Association of Urology; 2022. https://uroweb.org/guideline/non-muscle invasive-bladder-cancer/

Ramezani M, Siami, S, Rezaei M, et al. Immunohistochemical Study of c-erbB2/HER2 Tumor Marker in Primary Malignant Brain Tumors. Preprints.org 2018, 2018120017. https://doi.org/10.20944/ preprints 201812.0017.v1.

Ali MY, El-Esawy BH. Her2/neu expression in urothelial dysplasia, carcinoma in situ, and superficial urothelial carcinoma and its value in assessing the response to BCG therapy. Egyptian Journal of Pathology. 2014; 34:25-31.

Remy E, Rebouissou S, Chaouiya C, et al. A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis Mathematical Model of Bladder Tumorigenesis. Cancer Res. 2015; 75:4042-4052.

Hegazy R, Kamel M, Salem EA, et al. The prognostic significance of p53, p63 and Her2 expression in nonmuscle- invasive bladder cancer in relation to treatment with bacille Calmette-Guerin. Arab J Urol. 2015; 13:225-230.

Kumar S, Prajapati O, Vaiphei K, et al. Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: is it worth hype? South Asian J Cancer. 2015; 4:115-117.

Agrawal V, Bharti N, Pandey R. Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapy. Arab Journal of Urology. 2020; 18:267-72.

Eriksson P, Rovira C, Liedberg F, et al. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep. 2018; 8:1-2.

Bellmunt J, Werner L, Bamias A, et al. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015; 4:844-852.

Akgül M, Baykan Ö, Çag˘man Z, et al. Gas6 expression and Tyrosine kinase Axl Sky receptors: Their relation with tumor stage and grade in patients with bladder cancer. Arch Ital Urol Androl. 2021; 93:148-152.

Mitrakas L, Gravas S, Karasavvidou F, et al. Endothelin-1 indicates unfavorable prognosis in primary high-grade non-muscle-invasive urothelial bladder cancer. Arch Ital Urol Androl. 2021; 93:143-147.

Lim SD, Cho YM, Choi GS, et al. Clinical significance of substaging and HER2 expression in papillary non-muscle invasive urothelial cancers of the urinary bladder. J Korean Med Sci. 2015; 30:1068-1077.

Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate-and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010; 57:766-773.

Morgan BE, Salup R, Morgan MB. Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder. Urol Oncol. 2002; 7:67-72.

Trigo S, Gonzalez K, Di Matteo L, et al. Bacillus Calmette-Guerin vaccine and bladder cancer incidence: Scoping literature review and preliminary analysis. Arch Ital Urol Androl. 2021; 93:1-8.

Ali, M. Y., Aboelsaad, A. Y., Abdel Gawad, A. M., Abouelgreed, T. A., El Gammal, A. A., Ghoneimy, O. M., El-Dydamony, E. M., Alrefaey, A. A., Mohamed, E., Azzam, S., Abdulmohaymen, A., Mohammed, Y., Abdelwahed, M. S., Elsayed, A. F. A., Fathi, B. A., Abd Alrahim, N. M., Farag, A. S., Mahmoud, A. R., Mohamed, H. I., Horsu, S., & Hasan, A. (2023). HER2/neu expression status of post BCG recurrent non-muscle-invasive bladder urothelial carcinomas in relation to their primary ones. Archivio Italiano Di Urologia E Andrologia, 95(2). https://doi.org/10.4081/aiua.2023.11313

Download Citation

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Downloads

Download data is not yet available.

Citations

HER2/neu expression status of post BCG recurrent non-muscle-invasive bladder urothelial carcinomas in relation to their primary ones

Authors

Downloads

Citations

flyer

authors

reviewers

indexing

Keywords

Role of ureteral stent material and coating to prevent ureteral stent related issue: A systematic review and meta analysis

Cellular senescence in testicular cancer. Is there a correlation with the preoperative markers and the extent of the tumor? An experimental study

Ureteral stent related symptoms: A comparative study

Clinical characteristics of adult cases with urolithiasis from Turkey: A regional epidemiological study